The nature of investing is that you win some, and you lose some. Unfortunately, shareholders of Alphamab Oncology (HKG:9966) have suffered share price declines over the last year. The share price has slid 67% in that time. Because Alphamab Oncology hasn't been listed for many years, the market is still learning about how the business performs. More recently, the share price has dropped a further 28% in a month. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.

After losing 7.4% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.

View our latest analysis for Alphamab Oncology

Alphamab Oncology isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

A Different Perspective

Alphamab Oncology shareholders are down 67% for the year, even worse than the market loss of 26%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. With the stock down 27% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Given the relatively short history of this stock, we'd remain pretty wary until we see some strong business performance. You could get a better understanding of Alphamab Oncology's growth by checking out this more detailed historical graph of earnings, revenue and cash flow.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on HK exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.